![]()
Gene-Chemical Interaction Annotations Click to see Annotation Detail View
Term | Qualifier | Evidence | With | Reference | Notes | Source | Original Reference(s) | 1,1,1-trichloro-2,2-bis(4-hydroxyphenyl)ethane | decreases expression | ISO | RGD:1615521 | 6480464 | 2 more ... | CTD | PMID:25575267 | 1,2-dimethylhydrazine | multiple interactions | ISO | RGD:1615521 | 6480464 | [1, 2-Dimethylhydrazine co-treated with Folic Acid] results in increased expression of CNRIP1 mRNA | CTD | PMID:22206623 | 17beta-estradiol | decreases expression | ISO | RGD:1615521 | 6480464 | Estradiol results in decreased expression of CNRIP1 mRNA | CTD | PMID:25575267 | 2,3,7,8-tetrachlorodibenzodioxine | multiple interactions | ISO | RGD:1615521 | 6480464 | Tetrachlorodibenzodioxin promotes the reaction [AHR protein binds to CNRIP1 promoter] | CTD | PMID:19654925 | 3,3',4,4',5-pentachlorobiphenyl | decreases expression | ISO | RGD:1318105 | 6480464 | 3 more ... | CTD | PMID:23146750 | aflatoxin B1 | increases expression | ISO | RGD:1318105 | 6480464 | Aflatoxin B1 results in increased expression of CNRIP1 mRNA | CTD | PMID:22100608 | aflatoxin B1 | decreases methylation | ISO | RGD:1318105 | 6480464 | Aflatoxin B1 results in decreased methylation of CNRIP1 gene | CTD | PMID:27153756 | all-trans-retinoic acid | decreases expression | EXP | | 6480464 | Tretinoin results in decreased expression of CNRIP1 mRNA | CTD | PMID:20488242 | arsenite(3-) | multiple interactions | ISO | RGD:1318105 | 6480464 | arsenite promotes the reaction [G3BP1 protein binds to CNRIP1 mRNA] | CTD | PMID:32406909 | benzo[a]pyrene | increases methylation | ISO | RGD:1318105 | 6480464 | Benzo(a)pyrene results in increased methylation of CNRIP1 exon | CTD | PMID:27901495 | bis(2-ethylhexyl) phthalate | decreases expression | ISO | RGD:1318105 | 6480464 | Diethylhexyl Phthalate results in decreased expression of CNRIP1 mRNA | CTD | PMID:31163220 | bisphenol A | decreases expression | ISO | RGD:1615521 | 6480464 | bisphenol A results in decreased expression of CNRIP1 mRNA | CTD | PMID:25575267 | bisphenol A | multiple interactions | ISO | RGD:1318105 | 6480464 | [bisphenol A co-treated with Fulvestrant] results in increased methylation of CNRIP1 gene | CTD | PMID:31601247 | bisphenol A | decreases expression | EXP | | 6480464 | bisphenol A results in decreased expression of CNRIP1 mRNA | CTD | PMID:25181051, PMID:34947998 | cyclosporin A | increases expression | ISO | RGD:1318105 | 6480464 | Cyclosporine results in increased expression of CNRIP1 mRNA | CTD | PMID:20106945 | decabromodiphenyl ether | increases expression | ISO | RGD:1318105 | 6480464 | decabromobiphenyl ether results in increased expression of CNRIP1 protein | CTD | PMID:31675489 | diethylstilbestrol | decreases expression | ISO | RGD:1615521 | 6480464 | Diethylstilbestrol results in decreased expression of CNRIP1 mRNA | CTD | PMID:25575267 | dorsomorphin | multiple interactions | ISO | RGD:1318105 | 6480464 | [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 more ... | CTD | PMID:27188386 | entinostat | multiple interactions | ISO | RGD:1318105 | 6480464 | [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CNRIP1 mRNA | CTD | PMID:27188386 | entinostat | increases expression | ISO | RGD:1318105 | 6480464 | entinostat results in increased expression of CNRIP1 mRNA | CTD | PMID:26272509 | estriol | decreases expression | ISO | RGD:1615521 | 6480464 | Estriol results in decreased expression of CNRIP1 mRNA | CTD | PMID:25575267 | fenthion | increases expression | ISO | RGD:1615521 | 6480464 | Fenthion results in increased expression of CNRIP1 mRNA | CTD | PMID:34813904 | folic acid | multiple interactions | ISO | RGD:1615521 | 6480464 | [1, 2-Dimethylhydrazine co-treated with Folic Acid] results in increased expression of CNRIP1 mRNA | CTD | PMID:22206623 | fulvestrant | multiple interactions | ISO | RGD:1318105 | 6480464 | [bisphenol A co-treated with Fulvestrant] results in increased methylation of CNRIP1 gene | CTD | PMID:31601247 | gentamycin | decreases expression | EXP | | 6480464 | Gentamicins results in decreased expression of CNRIP1 mRNA | CTD | PMID:33387578 | kainic acid | increases expression | EXP | | 6480464 | Kainic Acid results in increased expression of CNRIP1 mRNA | CTD | PMID:22079489 | lead(0) | affects expression | ISO | RGD:1318105 | 6480464 | Lead affects the expression of CNRIP1 mRNA | CTD | PMID:28903495 | lead(2+) | affects expression | ISO | RGD:1318105 | 6480464 | Lead affects the expression of CNRIP1 mRNA | CTD | PMID:28903495 | methidathion | increases expression | ISO | RGD:1615521 | 6480464 | methidathion results in increased expression of CNRIP1 mRNA | CTD | PMID:34813904 | methylmercury chloride | decreases expression | ISO | RGD:1318105 | 6480464 | methylmercuric chloride results in decreased expression of CNRIP1 mRNA | CTD | PMID:28001369 | oxaliplatin | multiple interactions | EXP | | 6480464 | [oxaliplatin co-treated with Topotecan] results in increased expression of CNRIP1 mRNA | CTD | PMID:25729387 | ozone | multiple interactions | ISO | RGD:1615521 | 6480464 | [Air Pollutants results in increased abundance of Ozone] which results in decreased expression of CNRIP1 mRNA | CTD | PMID:34911549 | panobinostat | multiple interactions | ISO | RGD:1318105 | 6480464 | [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CNRIP1 mRNA | CTD | PMID:27188386 | panobinostat | increases expression | ISO | RGD:1318105 | 6480464 | panobinostat results in increased expression of CNRIP1 mRNA | CTD | PMID:26272509 | paracetamol | increases expression | ISO | RGD:1318105 | 6480464 | Acetaminophen results in increased expression of CNRIP1 mRNA | CTD | PMID:21420995 | phenylmercury acetate | decreases expression | ISO | RGD:1318105 | 6480464 | Phenylmercuric Acetate results in decreased expression of CNRIP1 mRNA | CTD | PMID:26272509 | phenylmercury acetate | multiple interactions | ISO | RGD:1318105 | 6480464 | [NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CNRIP1 mRNA | CTD | PMID:27188386 | pioglitazone | multiple interactions | ISO | RGD:1615521 | 6480464 | [N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of CNRIP1 mRNA | CTD | PMID:27935865 | pirinixic acid | multiple interactions | ISO | RGD:1318105 | 6480464 | [pirinixic acid binds to and results in increased activity of PPARA protein] which results in decreased expression of CNRIP1 mRNA | CTD | PMID:19710929 | pirinixic acid | multiple interactions | ISO | RGD:1615521 | 6480464 | [pirinixic acid binds to and results in increased activity of PPARA protein] which results in increased expression of CNRIP1 mRNA | CTD | PMID:19710929 | pregnenolone 16alpha-carbonitrile | increases expression | ISO | RGD:1615521 | 6480464 | Pregnenolone Carbonitrile results in increased expression of CNRIP1 mRNA | CTD | PMID:22698814 | SB 431542 | multiple interactions | ISO | RGD:1318105 | 6480464 | [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 more ... | CTD | PMID:27188386 | sodium arsenite | increases expression | ISO | RGD:1318105 | 6480464 | sodium arsenite results in increased expression of CNRIP1 mRNA | CTD | PMID:22714537, PMID:29301061 | temozolomide | increases expression | ISO | RGD:1318105 | 6480464 | Temozolomide results in increased expression of CNRIP1 mRNA | CTD | PMID:31758290 | topotecan | multiple interactions | EXP | | 6480464 | [oxaliplatin co-treated with Topotecan] results in increased expression of CNRIP1 mRNA | CTD | PMID:25729387 | trichloroethene | increases expression | EXP | | 6480464 | Trichloroethylene results in increased expression of CNRIP1 mRNA | CTD | PMID:33387578 | trichostatin A | increases expression | ISO | RGD:1318105 | 6480464 | trichostatin A results in increased expression of CNRIP1 mRNA | CTD | PMID:24935251, PMID:26272509 | trichostatin A | multiple interactions | ISO | RGD:1318105 | 6480464 | [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CNRIP1 mRNA | CTD | PMID:27188386 | valproic acid | affects expression | ISO | RGD:1318105 | 6480464 | Valproic Acid affects the expression of CNRIP1 mRNA | CTD | PMID:25979313 | valproic acid | decreases expression | ISO | RGD:1318105 | 6480464 | Valproic Acid results in decreased expression of CNRIP1 mRNA | CTD | PMID:28001369 | valproic acid | increases expression | ISO | RGD:1318105 | 6480464 | Valproic Acid results in increased expression of CNRIP1 mRNA | CTD | PMID:23179753 more ... | valproic acid | multiple interactions | ISO | RGD:1318105 | 6480464 | [NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CNRIP1 mRNA | CTD | PMID:27188386 | vorinostat | increases expression | ISO | RGD:1318105 | 6480464 | vorinostat results in increased expression of CNRIP1 mRNA | CTD | PMID:26272509 | vorinostat | multiple interactions | ISO | RGD:1318105 | 6480464 | [NOG protein co-treated with Vorinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CNRIP1 mRNA | CTD | PMID:27188386 | WIN 55212-2 | multiple interactions | ISO | RGD:1615521 | 6480464 | CNRIP1 protein inhibits the reaction [(3R)-((2 more ... | CTD | PMID:27513693 | |